Editorial
 SURVEY OF SPURIOUS DRUGS   
 Wednesday, October 29, 2014 
 The Centre has decided to conduct an all India survey on the extent of availability of spurious and not-of-standard quality drugs in the country. It is expected to be a broad-based survey covering 42,000 samples belonging to 15 therapeutic groups drawn from across the country listed in National List of Essential Medicines. 
  Past Editorial...  
TODAY'S NEWS
18:55  [IST]CPhI Worldwide 2014 draws 36,000 professionals, 2,500 exhibitors
18:50  [IST]Marksans Pharma net jumps up by 56% to Rs. 31 cr
18:00  [IST]Polyplus-transfection, Blue Sky ink research and commercial licence pact for use of PEI-based transfection technologies
17:00  [IST]Bristol-Myers Squibb announces results from CheckMate -063
16:40  [IST]NIMHANS director selected for Karnataka Rajyotsava award
16:00  [IST]Boehringer Ingelheim, Lilly revises diabetes alliances in certain countries
more news >>
TOP NEWS
08:00  [IST]CDSCO forms 5-member panel headed by Dr. Jagashetty to review manpower structure of CDL, Kolkata
08:00  [IST]Medicine marketing in Kerala turning into a monopoly of north Indian pharma cos
08:00  [IST]Alarmingly high burden of DR-TB among HIV-positive patients at ART centres in Mumbai: MSF study
08:00  [IST]Manipal Univ to host 4th annual conference on Mitochondrial Research and Medicine on December 8 & 9
08:00  [IST]DBT, NCI begin series of Provocative Questions workshops on Cancer Biology in India
08:00  [IST]DCGI to approve clinical trial proposals for new drugs approved abroad, FDCs, subsequent new drugs & vaccines
more news >>
YESTERDAY'S NEWS
18:00  [IST]Pfizer's Pristiq clinical study shows low potential for sexual dysfunction in MDD patients
17:00  [IST]Alnylam files clinical trial application to begin phase 1 Study with ALN-PCSsc to treat hypercholesterolemia
16:30  [IST]Neuland Laboratories net up by 50% in Q2
16:20  [IST]Sanofi net moves up by 9% to € 2.7 bn in Q3
14:50  [IST]Ajanta Pharma consolidated net surges by 41% in Q2
14:30  [IST]Novartis net profit jumps by 45% in Q3 to $3.2 bn
more news >>
INTERVIEW  
Life sciences an important industry for Information Technology companies
Ramesh J. Chougule, Associate Vice President, Life Sciences and Services, Infosys, tells Nandita Vijay
Past Interviews...
 
  What's New?  
 
Opinion Poll
 
 
Is the union health ministry's recent move to increase the number of drugs covered under the national list of essential medicines (NLEM) justified?
 
 
 
 

   
 
 
  Corporate
Pharma Stocks
Executive Diary
Pharma People
Product Launches
  Special Features
Features
  Chronicle Pharmabiz Specials
Forthcoming
  Past
 
  Forthcoming Events
International
  Domestic
 
TENDERS & PROJECTS
Tenders & Enquiries
Pharma Projects
CORPORATE
Company Profile
Corporate Results
Corporate X-ray
Pharmabiz Studies of Top Companies
US FDA UPDATE
US FDA: ANDA
US FDA: Warnings
US FDA: Approved NMEs
US FDA: New Approvals
US FDA: REFUSAL
EXPORT & IMPORT
Drug Export Procedures
Drug Units With WHO GMP Certification
Pharma Export Data
Import Reg. Update
PHARMA LAWS & DOCUMENTS
Notifications
Pharma Regulations
Patent Laws and Amendments
Patent Scan
Documents
New Drug Approvals
Notified Prices
LIST OF LABS & GOVT. BODIES
Govt Recognised In-House R&D Units
AICTE Boards & Committees
List of Indian CROs
List of CROs (International)
Govt & approved labs of India
List of State Drugs Controllers
 
 
 
 
 
 
Copyright © 2010 Saffron Media Pvt. Ltd |